Skip to content

Study · Randomized controlled trial · 1996

7 results

Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study.

Benagiano G, Kivinen ST, Fadini R, Cronjé H, Klintorp S, van der Spuy ZM

Fertility and sterility1 Aug 1996Cited by 27 (Europe PMC)

PMID8690106 (opens in a new tab)DOI10.1016/s0015-0282(16)58443-x (opens in a new tab)PepBankPUB-08690106
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with leiomyomata and anemia, goserelin plus iron increased hemoglobin versus iron alone, with a difference just over 1 g/dL.

    In plain wordsGoserelin plus iron increased hemoglobin versus iron alone in women with leiomyomata and anemia.

    Peptide
    Goserelin
    Outcome
    IncreasePreoperative hemoglobin
    Study

    n: not reported in source

    Comparator
    Iron alone
    Outcome group
    Overall treatment effect · Whole body
    Studied dose
    3.6 mg once monthly · 12 weeksAs given in this study (human).

    Measurements

    Difference in least square means of hemoglobin
    > 1 g/dL
    goserelin acetate plus iron vs iron only

    Source sentences

    Summary
    Considering the entry and preoperative hemoglobin concentrations, there was a difference in least square means of just over 1 g/dL between the goserelin acetate plus iron and iron only groups
    4 context sentences
    Summary · context
    These differences were both statistically significant.
    Summary · context
    Multinational, multicenter, prospective, randomized, double-blind study.PatientsPremenopausal women with menorrhagia or metrorrhagia and anemia associated with uterine leiomyomata awaiting hysterectomy.
    Summary · context
    Patients were randomized to one of three 12-week treatment groups namely goserelin acetate 3.6 mg once monthly plus placebo iron; 3.6 mg goserelin acetate once monthly plus 600 mg/d iron; or sham injection once monthly plus 600 mg/d iron.
    Summary · context
    goserelin acetate in combination with iron therapy has shown significant advantages over the iron alone in restoring hematologic normality
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with leiomyomata and anemia, uterine volume decreased significantly more with goserelin plus iron than iron alone.

    In plain wordsUterine volume decreased more with goserelin plus iron than iron alone.

    Peptide
    Goserelin
    Outcome
    DecreaseUterine volume
    Study

    n: not reported in source

    Comparator
    Iron alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg once monthly · 12 weeksAs given in this study (human).

    Measurements

    Uterine volume decrease
    37 to 40%
    goserelin-treated groups (both goserelin arms pooled in source)
    Uterine volume decrease
    7%
    iron only group

    Source sentences

    Summary
    Uterine and fibroid volumes were decreased in the goserelin acetate-treated patients by between 37% and 40% and 44% and 47%, respectively, compared with 7% decreases for both in the iron only group. The differences in absolute changes were statistically significant for both the goserelin acetate-tre…
    2 context sentences
    Summary · context
    Multinational, multicenter, prospective, randomized, double-blind study.PatientsPremenopausal women with menorrhagia or metrorrhagia and anemia associated with uterine leiomyomata awaiting hysterectomy.
    Summary · context
    Patients were randomized to one of three 12-week treatment groups namely goserelin acetate 3.6 mg once monthly plus placebo iron; 3.6 mg goserelin acetate once monthly plus 600 mg/d iron; or sham injection once monthly plus 600 mg/d iron.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with leiomyomata and anemia, fibroid volume decreased significantly more with goserelin plus iron than iron alone.

    In plain wordsFibroid volume decreased more with goserelin plus iron than iron alone.

    Peptide
    Goserelin
    Outcome
    DecreaseFibroid volume
    Study

    n: not reported in source

    Comparator
    Iron alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg once monthly · 12 weeksAs given in this study (human).

    Measurements

    Fibroid volume decrease
    44 to 47%
    goserelin-treated groups (both goserelin arms pooled in source)
    Fibroid volume decrease
    7%
    iron only group

    Source sentences

    Summary
    Uterine and fibroid volumes were decreased in the goserelin acetate-treated patients by between 37% and 40% and 44% and 47%, respectively, compared with 7% decreases for both in the iron only group. The differences in absolute changes were statistically significant for both the goserelin acetate-tre…
    2 context sentences
    Summary · context
    Multinational, multicenter, prospective, randomized, double-blind study.PatientsPremenopausal women with menorrhagia or metrorrhagia and anemia associated with uterine leiomyomata awaiting hysterectomy.
    Summary · context
    Patients were randomized to one of three 12-week treatment groups namely goserelin acetate 3.6 mg once monthly plus placebo iron; 3.6 mg goserelin acetate once monthly plus 600 mg/d iron; or sham injection once monthly plus 600 mg/d iron.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with leiomyomata and anemia, operative blood loss was lower with goserelin plus iron than iron alone.

    In plain wordsOperative blood loss was lower with goserelin plus iron than iron alone.

    Peptide
    Goserelin
    Outcome
    DecreaseOperative blood loss
    Study

    n: not reported in source

    Comparator
    Iron alone
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    3.6 mg once monthly · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The least square geometric mean operative blood loss was greatest in the iron only group.
    2 context sentences
    Summary · context
    Multinational, multicenter, prospective, randomized, double-blind study.PatientsPremenopausal women with menorrhagia or metrorrhagia and anemia associated with uterine leiomyomata awaiting hysterectomy.
    Summary · context
    Patients were randomized to one of three 12-week treatment groups namely goserelin acetate 3.6 mg once monthly plus placebo iron
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with leiomyomata and anemia, uterine volume decreased significantly more with goserelin alone than iron alone; decreases across both goserelin arms ranged from 37% to 40%, versus 7% with iron alone.

    In plain wordsUterine volume decreased more with goserelin alone than iron alone.

    Peptide
    Goserelin
    Outcome
    DecreaseUterine volume
    Study

    n: not reported in source

    Comparator
    Iron alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg once monthly · 12 weeksAs given in this study (human).

    Measurements

    Uterine volume decrease
    37 to 40%
    goserelin-treated groups (both goserelin arms pooled in source)
    Uterine volume decrease
    7%
    iron only group

    Source sentences

    Summary
    Uterine and fibroid volumes were decreased in the goserelin acetate-treated patients by between 37% and 40% and 44% and 47%, respectively, compared with 7% decreases for both in the iron only group. The differences in absolute changes were statistically significant for both the goserelin acetate-tre…
    2 context sentences
    Summary · context
    Multinational, multicenter, prospective, randomized, double-blind study.PatientsPremenopausal women with menorrhagia or metrorrhagia and anemia associated with uterine leiomyomata awaiting hysterectomy.
    Summary · context
    Patients were randomized to one of three 12-week treatment groups namely goserelin acetate 3.6 mg once monthly plus placebo iron; 3.6 mg goserelin acetate once monthly plus 600 mg/d iron; or sham injection once monthly plus 600 mg/d iron.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with leiomyomata and anemia, fibroid volume decreased significantly more with goserelin alone than iron alone; decreases across both goserelin arms ranged from 44% to 47%, versus 7% with iron alone.

    In plain wordsFibroid volume decreased more with goserelin alone than iron alone.

    Peptide
    Goserelin
    Outcome
    DecreaseFibroid volume
    Study

    n: not reported in source

    Comparator
    Iron alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg once monthly · 12 weeksAs given in this study (human).

    Measurements

    Fibroid volume decrease
    44 to 47%
    goserelin-treated groups (both goserelin arms pooled in source)
    Fibroid volume decrease
    7%
    iron only group

    Source sentences

    Summary
    Uterine and fibroid volumes were decreased in the goserelin acetate-treated patients by between 37% and 40% and 44% and 47%, respectively, compared with 7% decreases for both in the iron only group. The differences in absolute changes were statistically significant for both the goserelin acetate-tre…
    2 context sentences
    Summary · context
    Multinational, multicenter, prospective, randomized, double-blind study.PatientsPremenopausal women with menorrhagia or metrorrhagia and anemia associated with uterine leiomyomata awaiting hysterectomy.
    Summary · context
    Patients were randomized to one of three 12-week treatment groups namely goserelin acetate 3.6 mg once monthly plus placebo iron; 3.6 mg goserelin acetate once monthly plus 600 mg/d iron; or sham injection once monthly plus 600 mg/d iron.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with leiomyomata and anemia, operative blood loss was lower with goserelin alone than iron alone.

    In plain wordsOperative blood loss was lower with goserelin alone than iron alone.

    Peptide
    Goserelin
    Outcome
    DecreaseOperative blood loss
    Study

    n: not reported in source

    Comparator
    Iron alone
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    3.6 mg once monthly · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The least square geometric mean operative blood loss was greatest in the iron only group.
    2 context sentences
    Summary · context
    Multinational, multicenter, prospective, randomized, double-blind study.PatientsPremenopausal women with menorrhagia or metrorrhagia and anemia associated with uterine leiomyomata awaiting hysterectomy.
    Summary · context
    Patients were randomized to one of three 12-week treatment groups namely goserelin acetate 3.6 mg once monthly plus placebo iron; 3.6 mg goserelin acetate once monthly plus 600 mg/d iron; or sham injection once monthly plus 600 mg/d iron.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.